Phase II study of sorafenib in malignant mesothelioma previously treated with platinum-based chemotherapy

Registry ID

EUCTR2007-005091-13

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

Guy's & St Thomas' NHS Foundation Trust

Start date

2008-01-02

Completion date

2012-10-12

Last update

2026-08-16

Conditions

• Malignant Mesothelioma

Summary

To determine the progression-free survival in patients with malignant mesothelioma receiving oral sorafenib 400mg BD daily.

Locations

• , , UK

Related clinical trials

• Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
• A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
• Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
• Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
• Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

View on source registry